Cervical Cancer in the Current Age: Quo Vadis?
References
- World Health Organization. Cervical cancer [Internet]. Geneva: WHO; 2023 [cited 2025 Sep 27]. Available from: https://www.who.int/news-room/fact-sheets/detail/cervical-cancer
- American Cancer Society. Understanding What Cancer Is: Ancient Times to Present. [Internet]. American Cancer Society; [cited 2025 Sep 27]. Available from: https://www.cancer.org/cancer/understanding-cancer/history-of-cancer/what-is-cancer.html
- Rigoni S. Statistical facts about cancers on which Doctor Rigoni-Stern based his contribution to the Surgeons’ Subgroup of the IV Congress of Italian Scientists on 23 September 1842 (translation). Stat Med. 1987;6:881–4
- Bosch FX, Lorincz A, Munoz N, et al. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002;55:244–65
- Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12–19
- Bettio M, Dimitrova N, Florensa Molist M, Randi G, Giusti F, Martos Jimenez MDC, et al. Cervical cancer burden in EU-27. Luxembourg: European Commission; 2021. Report No.: JRC127180.
- World Health Organization. Global strategy to accelerate the elimination of cervical cancer as a public health problem [Internet]. Geneva: WHO; [cited 2025 May 24]. Disponibil la: https://www.who.int/publications/i/item/9789240014107
- Chatterjee PB, Hingway SR, Hiwale KM. Evolution of Pathological Techniques for the Screening of Cervical Cancer: A Comprehensive Review. Cureus. 2024 May 21;16(5):e60769
- Boon SS, Luk HY, Xiao C, Chen Z, Chan PKS. Review of the Standard and Advanced Screening, Staging Systems and Treatment Modalities for Cervical Cancer. Cancers 2022;14:2913
- Polten R, Ghaffari T, Rezaei N, Alizadeh-Ghodsi M, Wendt C, Muzzio DO, et al. Towards novel gene and cell therapy approaches for cervical cancer. Cancers (Basel). 2023 Jan 2;15(1):263
- Dicu-Andreescu IG, Marincaș AM, Ungureanu VG, Ionescu SO, Prunoiu VM, Brătucu E, Simion L. Current therapeutic approaches in cervical cancer based on the stage of the disease: Is there room for improvement? Medicina (Kaunas). 2023 Jun 30;59(7):1229
- Faye MD, Alfieri J. Advances in Radiation Oncology for the Treatment of Cervical Cancer. Current Oncology 2022;29:928–44
- Manso L, Ramchandani-Vaswani A, Romero I, de la Orden V, Santaballa A, Redondo A, et al. SEOM-GEICO clinical guidelines on cervical cancer (2023). Clin Transl Oncol. 2024 Feb;26(2):2771-2782.
- Tewari KS, Sill MW, Long HJ, Penson RT, Huang H, Ramondetta LM, et al. Final overall survival analysis of the phase III randomized trial of chemotherapy with and without bevacizumab for advanced cervical cancer: an NRG Oncology–Gynecologic Oncology Group study. Ann Oncol. 2019 Feb;30(4):564-571
- Ferrall L, Lin KY, Roden RBS, Hung CF, Wu TC. Cervical cancer immunotherapy: facts and hopes. Clin Cancer Res. 2021 Mar 15;27(6):1678-1693
- Lee SJ, Yang A, Wu TC, Hung CF. Immunotherapy for human papillomavirus-associated disease and cervical cancer: review of clinical and translational research. Clin Cancer Res. 2019 Feb 15;25(4):1244-1251
- Sherer MV, Kotha NV, Williamson CW, Mayadev J. Advances in immunotherapy for cervical cancer: recent developments and future directions. Int J Mol Sci. 2022 Dec 15;23(24):15929
- Filipić B, Ferk P, Šterbenc A, Fink D, Cerar O, Seme K, et al. Human papillomaviruses and cervical cancer from the perspective of the World Health Organization initiative for cervical cancer elimination. Cancers. 2022 Jul 28;14(15):3786
- Bhatla N, Berek JS, Cuello Fredes M, Denny LA, Grenman S, Karunaratne K, et al. Revised FIGO staging for carcinoma of the cervix uteri. Int J Gynaecol Obstet. 2019 Apr;145(1):129-135
- Societatea de Obstetrică şi Ginecologie din România, Colegiul Medicilor din România. Ghid clinic – Cancerul de col uterin. Revizuit 2024
- Mayadev J, Nunes AT, Li M, Nazzaro CA, Mao L, Chou J, et al. Atezolizumab as an immune primer with extended field chemoradiotherapy for node-positive locally advanced cervical cancer: safety and immunogenicity results from NRG-GY017. Gynecol Oncol. 2023 Feb;170:39-46.
- Duska LR, Tewari KS, Pignata S, Colombo N, Ramirez PT, Holloway RW, et al. Pembrolizumab with chemoradiotherapy in patients with high-risk locally advanced cervical cancer: final analysis results of the phase 3 randomized double-blind ENGOT-cx11/GOG-3047/KEYNOTE-A18 study. J Clin Oncol. 2025;43(suppl LBA5504):LBA5504.
- Lorusso D, Petrelli F, Coinu A, Raspagliesi F, Barni S. A systematic review comparing cisplatin and carboplatin plus paclitaxel-based chemotherapy for recurrent or metastatic cervical cancer. Gynecol Oncol. 2014 Apr;133(1):117-123
- Crafton SM, Venkat PS, Salani R. A review of the state of cervical cancer: updates from prevention to recurrent disease. Curr Opin Obstet Gynecol. 2024 Feb;36(1):28-33
- Hildesheim A, Gonzalez P, Kreimer AR, Wacholder S, Schussler J, Rodriguez AC, et al. Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment. Am J Obstet Gynecol. 2016 Aug;215(2):212.e1-212.e15.
- Zia S, Yildiz-Aktas IZ, Zia F, et al. An update on applications of digital pathology: primary diagnosis, telepathology, education and research. Diagn Pathol. 2025;20:17.
- Hanna MG, Pantanowitz L. Digital pathology. In: Narayan R, editor. Encyclopedia of biomedical engineering. Amsterdam: Elsevier; 2019. p. 524–32.
- Huang C, Luo X, Wang S, Wan Y, Wang J, Tang X, et al. Minimally invasive cytopathology and accurate diagnosis: technical procedures and ancillary techniques. In Vivo. 2023;37:11.
- Yang Y, Guan S, Ou Z, Li W, Yan L, Situ B. Advances in AI‐based cancer cytopathology. Interdiscip Med. 2023.
- Huang S, Yang J, Fong S, Zhao Q. Artificial intelligence in cancer diagnosis and prognosis: opportunities and challenges. Cancer Lett. 2020;471:61.
- Chen ZE, Lin F. Overview of predictive biomarkers and integration of IHC into molecular pathology. In: Fan L, Jeffrey P, editors. Handbook of practical immunohistochemistry: frequently asked questions. 2nd ed. New York: Springer; 2015.
- Yong WH, Dry SM, Shabihkhani M. A practical approach to clinical and research biobanking. Methods Mol Biol. 2014;1180:137–62.
- Lin F, Chen Z. Standardization of diagnostic immunohistochemistry: literature review and Geisinger experience. Arch Pathol Lab Med. 2014;138:1564–77.
- An H, Ding L, Ma M, Huang A, Gan Y, Sheng D, et al. Deep learning-based recognition of cervical squamous interepithelial lesions. Diagnostics (Basel). 2023 May 12;13(10):1720.
- Joshua A, Allen KE, Orsi NM. An overview of artificial intelligence in gynaecological pathology diagnostics. Cancers. 2025;17(8):1343.
- Tang H-P, Cai D, Kong Y-Q, Ye H, Ma Z-X, Lv H-S, et al. Cervical cytology screening facilitated by an artificial intelligence microscope: a preliminary study. Cancer Cytopathol. 2021;129(10):693–700.
- Lai B, Fu J, Zhang Q, Deng N, Jiang Q, Peng J. Artificial intelligence in cancer pathology: challenge to meet increasing demands of precision medicine. Int J Oncol. 2023;63(3):107.
- Baeten IGT, Hoogendam JP, Stathonikos N, Gerestein CG, Jonges GN, van Diest PJ, et al. Artificial intelligence-based sentinel lymph node metastasis detection in cervical cancer. Cancers. 2024;16:3619.
- Zhu Y, Zhou J, Zhu L, Hu W, Liu B, Xie L. Adoptive tumor-infiltrating lymphocyte cell therapy for cervical cancer. Hum Vaccin Immunother. 2022 May;18(5):2060019
- Stevanović S, Draper LM, Langhan MM, Campbell TE, Kwong ML, Wunderlich JR, et al. Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells. J Clin Oncol. 2015 May 10;33(14):1543–50
- Stevanović S, Pasetto A, Helman SR, Gartner JJ, Prickett TD, Howie B, et al. Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer. Science. 2017 Apr 14;356(6334):200-205
- Stevanović S, Helman SR, Wunderlich JR, Langhan MM, Doran SL, Kwong MLM, et al. A phase II study of tumor-infiltrating lymphocyte therapy for human papillomavirus-associated epithelial cancers. Clin Cancer Res. 2019 Mar 1;25(5):1486-1493
- Grit Biotechnology. GT101: Autologous tumor-infiltrating lymphocyte therapy for recurrent or metastatic cervical cancer. ClinicalTrials.gov Identifier: NCT05430373. Available from: https://clinicaltrials.gov/study/NCT05430373
- Grit Biotechnology. GT201: Membrane-bound IL-15 engineered tumor-infiltrating lymphocyte therapy for advanced solid tumors. ClinicalTrials.gov Identifier: NCT05729399. Available from: https://clinicaltrials.gov/study/NCT05729399
- Jun Sai Biotech. GC101: Autologous tumor-infiltrating lymphocyte therapy for advanced solid tumors. ClinicalTrials.gov Identifier: NCT04691273. Available from: https://clinicaltrials.gov/study/NCT04691273
- Jun Sai Biotech. GC203: Genetically modified tumor-infiltrating lymphocyte therapy for advanced solid tumors. ClinicalTrials.gov Identifier: NCT05212345. Available from: https://clinicaltrials.gov/study/NCT05212345
- Guo J, Huang W, Zhao B, Yu J, Cui J, Sun J, et al. A first-in-human study of CRISPR/Cas9-engineered tumor-infiltrating lymphocytes (TILs) product GT316 as monotherapy in advanced solid tumors. J Clin Oncol. 2024 Jun 1;42(16_suppl):2549
- Aoto K, Mimura K, Okayama H, Saito M, Chida S, Noda M, et al. Immunogenic tumor cell death induced by chemotherapy in patients with breast cancer and esophageal squamous cell carcinoma. Oncol Rep. 2018 Jan;39(1):151-159.
- Koukourakis IM, Gkegka AG, Xanthopoulou E, Nanos C, Giatromanolaki A, Koukourakis MI. Prognostic and predictive relevance of tumor-infiltrating lymphocytes in squamous cell head-neck cancer patients treated with radical radiotherapy/chemo-radiotherapy. Curr Oncol. 2022 Jun;29(6):4274-4284.
- O’Malley D, Lee S, Psyrri A, Sukari A, Thomas S, Wenham R, et al. Phase 2 efficacy and safety of autologous tumor-infiltrating lymphocyte (TIL) cell therapy in combination with pembrolizumab in immune checkpoint inhibitor-naïve patients with advanced cancers. J Immunother Cancer. 2021;9(Suppl 2):A523–A524
- Yin H, Guo W, Sun X, Li R, Feng C, Tan Y. TILs and anti-PD1 therapy: An alternative combination therapy for PD-L1 negative metastatic cervical cancer. J Immunol Res. 2020;2020:8345235
- Ahluwalia MS, Rogers LR, Chaudhary R, Newton HB, Ozair A, Khosla AA, Nixon AB, Adams BJ, Seon BK, Peereboom DM, Theuer CP. Endoglin inhibitor TRC105 with or without bevacizumab for bevacizumab-refractory glioblastoma (ENDOT): a multicenter phase II trial. Commun Med (Lond). 2023 Sep 8;3(1):120
- Apolo AB, Karzai FH, Trepel JB, Alarcon S, Lee S, Lee MJ, Tomita Y, Cao L, Yu Y, Merino MJ, Madan RA, Parnes HL, Steinberg SM, Rodriguez BW, Seon BK, Gulley JL, Arlen PM, Dawson NA, Figg WD, Dahut WL. A Phase II Clinical Trial of TRC105 (Anti-Endoglin Antibody) in Adults With Advanced/Metastatic Urothelial Carcinoma. Clin Genitourin Cancer. 2017 Feb;15(1):77-85
- Choueiri TK, Zakharia Y, Pal S, et al. Clinical results and biomarker analyses of axitinib and TRC105 versus axitinib alone in patients with advanced or metastatic renal cell carcinoma (TRAXAR). Oncologist. 2021 Jul;26(7):560-e1103
- Serani S. Carotuximab shows promising safety in metastatic CRPC phase 2 trial. Targeted Oncology. 2025 Jul 18. Available from: https://www.targetedonc.com/view/carotuximab-shows-promising-safety-inmetastatic-crpc-phase-2-trial
- Jones RL, Ravi V, Brohl AS, et al. Efficacy and safety of TRC105 plus pazopanib vs pazopanib alone for treatment of patients with advanced angiosarcoma: a randomized clinical trial. JAMA Oncol. 2022 May 1;8(5):740-747
- Chung HC, Ros W, Delord JP, Perets R, Italiano A, Shapira-Frommer R, et al. Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol. 2019 Jun 10;37(17):1470-8
- Shieh KR, Huang A, Xu Y. Response to immune checkpoint inhibitor treatment in advanced cervical cancer and biomarker study. Front Med (Lausanne). 2021 Aug 12;8:669587
- Lorusso D, Xiang Y, Hasegawa K, Scambia G, Leiva M, Ramos-Elias P, et al. Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial. The Lancet 2024.
- Șerbănescu, L.; Rotar V.; Ionescu E.V.; Ciota A.E.; Mirea S.; Iopnescu P.; Costea A.C. The role of Kegel exercises in reducing involuntary loss of urine in overactive bladder and mixed urinary incontinence. Balneo and PRM Research Journal, 2024, 15(4), 757.
- Șerbănescu, L.; Rotar, V.; Brezeanu, D.; Mirea, S.; Ionescu, E. V.; Ionescu, P. Evaluating the Efficacy of Combined Intravaginal Estriol Therapy and Kegel Exercises in Managing Menopausal Atrophic Vulvovaginitis. Clin Pract, 2025, 15(1), 20.
Language: English
Page range: 141 - 148
Published on: Jun 13, 2026
Published by: Ovidius University of Constanta
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
Related subjects:
© 2026 Laura-Andra Petrica, Mariana Aşchie, Mariana Deacu, Georgeta Camelia Cozaru, Anca Florentina Mitroi, Gabriela Izabela Băltăţescu, Ana Maria Creţu, Andrei Radu Baz, published by Ovidius University of Constanta
This work is licensed under the Creative Commons Attribution 4.0 License.